Double maintains 1 strategies that include ALXO - ALX Oncology Holdings, Inc.
Yahoo
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date: Thursday, June 5, 2025Time: 1:25 PM ETLocation: New York, NYWebcast link: A
Yahoo
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026 - Trials evaluating the Company’s lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal canc
Yahoo
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the
Yahoo
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20Company will not pursue U.S. registrational
Yahoo
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. A
Yahoo
Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -25.72% | $295.67M | 1.43% |
| VIXY | -19.80% | $165.58M | 0.85% |
| TAIL | -18.45% | $99.49M | 0.59% |
| KRBN | -17.57% | $162.64M | 0.85% |
| XBIL | -14.84% | $783.84M | 0.15% |
| UTWO | -13.00% | $379.27M | 0.15% |
| IBTH | -12.28% | $1.60B | 0.07% |
| SCHO | -11.89% | $11.46B | 0.03% |
| STPZ | -11.61% | $450.05M | 0.2% |
| SPTS | -11.35% | $5.77B | 0.03% |
| DFNM | -11.34% | $1.57B | 0.17% |
| IBTF | -11.26% | $2.02B | 0.07% |
| SCMB | -10.96% | $2.04B | 0.03% |
| IDU | -10.95% | $1.42B | 0.39% |
| IVOL | -10.59% | $348.25M | 1.02% |
| STIP | -10.57% | $12.70B | 0.03% |
| IBTJ | -10.38% | $684.86M | 0.07% |
| XLU | -10.19% | $18.93B | 0.09% |
| BIL | -10.04% | $42.84B | 0.1356% |
| VPU | -10.01% | $7.01B | 0.09% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GNOM | 34.06% | $44.38M | 0.5% |
| IWC | 31.85% | $817.74M | 0.6% |
| QTUM | 28.49% | $1.56B | 0.4% |
| ARKG | 27.99% | $1.02B | 0.75% |
| KJUL | 27.59% | $119.28M | 0.79% |
| IWM | 27.45% | $63.18B | 0.19% |
| IBB | 27.43% | $5.28B | 0.45% |
| VTWO | 27.30% | $12.58B | 0.07% |
| XBI | 27.23% | $4.84B | 0.35% |
| IWN | 27.17% | $10.93B | 0.24% |
| BSVO | 27.14% | $1.47B | 0.47% |
| GSSC | 27.13% | $560.96M | 0.2% |
| IWO | 26.60% | $11.53B | 0.24% |
| ARKK | 26.36% | $6.78B | 0.75% |
| SCHA | 26.31% | $17.26B | 0.04% |
| PRFZ | 26.20% | $2.36B | 0.34% |
| EES | 25.97% | $584.75M | 0.38% |
| KRE | 25.90% | $3.39B | 0.35% |
| KBE | 25.88% | $1.49B | 0.35% |
| IAT | 25.81% | $632.05M | 0.4% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| AGZD | 0.01% | $102.60M | 0.23% |
| SPIP | -0.03% | $972.34M | 0.12% |
| USIG | 0.04% | $14.02B | 0.04% |
| UDN | 0.05% | $147.49M | 0.78% |
| SPSB | 0.06% | $8.35B | 0.04% |
| JPIB | 0.08% | $898.94M | 0.5% |
| USFR | 0.08% | $18.59B | 0.15% |
| IGEB | -0.14% | $1.26B | 0.18% |
| WIP | -0.14% | $382.35M | 0.5% |
| CORP | -0.17% | $1.33B | 0.23% |
| BSCV | -0.17% | $1.05B | 0.1% |
| TBIL | 0.27% | $5.83B | 0.15% |
| UUP | -0.28% | $209.45M | 0.77% |
| VRIG | 0.29% | $1.20B | 0.3% |
| SUSC | 0.33% | $1.16B | 0.18% |
| BSCP | 0.35% | $3.28B | 0.1% |
| QLTA | 0.37% | $1.63B | 0.15% |
| IBDW | -0.37% | $1.57B | 0.1% |
| BSCW | -0.37% | $908.36M | 0.1% |
| PSQA | -0.45% | $35.43M | 0.2% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BAND | 38.06% | $474.72M | -3.51% | 0.00% |
| COHU | 36.71% | $912.85M | -41.28% | 0.00% |
| MGNX | 35.21% | $79.49M | -69.27% | 0.00% |
| ARCT | 33.85% | $352.30M | -39.53% | 0.00% |
| MRNA | 33.79% | $11.10B | -75.49% | 0.00% |
| ALLO | 32.54% | $258.10M | -45.37% | 0.00% |
| TXG | 32.51% | $1.51B | -36.09% | 0.00% |
| PAX | 32.15% | $2.24B | +15.38% | 4.21% |
| LAB | 31.89% | $489.97M | -27.12% | 0.00% |
| WCC | 31.37% | $9.23B | +20.22% | 0.92% |
| BURL | 31.11% | $14.95B | +0.65% | 0.00% |
| RGNX | 31.08% | $414.70M | -23.44% | 0.00% |
| CGNX | 31.03% | $5.38B | -32.08% | 0.98% |
| AME | 30.80% | $42.26B | +10.21% | 0.64% |
| VNT | 30.75% | $5.54B | -2.09% | 0.27% |
| ZNTL | 30.64% | $85.62M | -66.67% | 0.00% |
| KLTR | 30.41% | $307.24M | +76.99% | 0.00% |
| ALEC | 30.39% | $141.99M | -67.28% | 0.00% |
| CRBU | 30.39% | $116.26M | -21.88% | 0.00% |
| NBHC | 30.32% | $1.49B | -0.91% | 2.96% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OLO | 0.01% | $1.48B | +106.51% | 0.00% |
| CPT | 0.03% | $12.07B | +3.71% | 3.68% |
| PRPO | 0.03% | $16.51M | +118.40% | 0.00% |
| MDT | -0.03% | $113.71B | +14.71% | 3.17% |
| UUU | -0.04% | $6.98M | +97.39% | 0.00% |
| USM | 0.08% | $5.46B | +16.18% | 0.00% |
| SHCO | 0.08% | $1.49B | +40.11% | 0.00% |
| AMH | -0.09% | $13.23B | -4.28% | 3.14% |
| DRVN | 0.09% | $2.97B | +37.55% | 0.00% |
| EHAB | 0.10% | $399.02M | -10.05% | 0.00% |
| SFM | -0.10% | $15.86B | +95.37% | 0.00% |
| BUD | -0.10% | $121.42B | +18.05% | 1.64% |
| VIV | 0.12% | $18.52B | +46.63% | 0.67% |
| EE | -0.13% | $911.59M | +53.92% | 0.72% |
| TXMD | 0.15% | $13.08M | -31.93% | 0.00% |
| CNK | -0.18% | $3.46B | +40.52% | 0.53% |
| LMAT | -0.20% | $1.89B | +3.08% | 0.87% |
| CELH | -0.21% | $11.87B | -19.64% | 0.00% |
| YORW | 0.22% | $465.42M | -13.07% | 2.67% |
| BAX | -0.22% | $16.03B | -4.93% | 2.57% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ED | -20.20% | $36.31B | +13.27% | 3.35% |
| EXC | -17.68% | $43.82B | +25.72% | 3.63% |
| SO | -17.27% | $101.44B | +19.02% | 3.16% |
| WEC | -16.39% | $33.43B | +34.23% | 3.33% |
| CHRW | -15.70% | $11.67B | +14.11% | 2.52% |
| DUK | -15.70% | $92.39B | +19.10% | 3.55% |
| K | -15.05% | $27.71B | +40.85% | 2.85% |
| CNP | -14.93% | $23.84B | +19.89% | 2.34% |
| VSTA | -13.99% | $341.66M | +42.00% | 0.00% |
| CTRE | -13.61% | $5.84B | +20.16% | 4.10% |
| COR | -13.56% | $57.24B | +32.73% | 0.74% |
| FE | -13.50% | $23.31B | +5.57% | 4.29% |
| CL | -13.31% | $74.59B | -4.24% | 2.20% |
| AEE | -13.11% | $26.67B | +34.81% | 2.88% |
| OHI | -12.94% | $10.61B | +8.08% | 7.30% |
| NOC | -12.62% | $72.47B | +15.13% | 1.72% |
| CALM | -12.57% | $5.43B | +64.80% | 6.59% |
| CWAN | -12.55% | $5.93B | +20.01% | 0.00% |
| KR | -12.33% | $47.17B | +41.48% | 1.81% |
| ABT | -12.13% | $237.07B | +32.03% | 1.68% |
Current Value
$0.431 Year Return
Current Value
$0.431 Year Return
